European Pharmaceutical Review

JUNE 28, 2024

The post <em>European Pharmaceutical Review </em> Issue 3 2024 appeared first on European Pharmaceutical Review.

Research Laboratories 52

Research Laboratories Vaccines Drug Development Immunity 52

European Pharmaceutical Review

JANUARY 16, 2023

The safety and efficacy of mRNA vaccines should be a game changer and is the likely solution to antibiotic-resistant microorganisms and emerging viral pathogens.” The previous record for vaccine development and approval was four years for the measles vaccine.

Vaccines 128

Vaccines Research Laboratories Documentation Compounding 128

Pharmaceutical Technology

FEBRUARY 20, 2023

The formal signing ceremony of the MoU today at Cerba Research’s Ghent office was led by Mario Papillon, CEO of Cerba Research, and Xu Yi, CEO of Teddy Lab, on behalf of their respective organisations. About Teddy Clinical Research Laboratory : As a joint venture company established in 2016 by Dian Diagnostics (300244.SZ)

Research Laboratories 52

Research Laboratories Drug Development Vaccines Communication 52

European Pharmaceutical Review

MARCH 12, 2025

MSD has announced it has opened a new $1 billion vaccine manufacturing facility at its site in Durham, North Carolina, US. Enhancing drug development capacity In October 2024, MSD acquired full global rights to the next generation CD3xCD19 bispecific antibody to treat B-cell associated diseases, from the biotech Curon Biopharmaceutical.

Research Laboratories 52

Research Laboratories Vaccines Drug Development 52